Internship

Intern – Discovery Biology

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Have completed two or three years at a US college or university at the time of the program
  • Have a GPA of at least 3.0 (4.0 scale)
  • Seeking a BS/MS/PhD degree in cell/molecular biology, biochemistry, and/or related fields
  • A self-starter with good communication skills, and enjoys working as a member of a multidisciplinary team in a fast-paced drug discovery environment
  • Experience in general laboratory techniques, data analysis, and computer software packages and databases are preferred
Responsibilities
  • Performing experiments in cardiac and skeletal muscle cells including measuring changes in mitochondrial function
  • Assessment of changes in mitochondrial morphology and membrane potential by fluorescence microscopy
  • Support in vitro and in vivo studies with other scientists within the department
  • Perform primary literature searches to identify novel drug targets for future development
  • Conduct data analysis and present findings to the research team
  • As a member of a multidisciplinary team, this person will work closely with team members to identify, characterize, and advance compounds through research and preclinical development

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?